<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02254018</url>
  </required_header>
  <id_info>
    <org_study_id>1191.2</org_study_id>
    <nct_id>NCT02254018</nct_id>
  </id_info>
  <brief_title>Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck</brief_title>
  <official_title>An Open Phase I Single Dose Escalation Study of Bivatuzumab Mertansine Administered Intravenously in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck With Repeated Administration in Patients With Clinical Benefit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of bivatuzumab mertansine
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <primary_completion_date type="Actual">February 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of bivatuzumab mertansine</measure>
    <time_frame>up to day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to day 21</time_frame>
    <description>grading according to the common toxicity criteria (CTC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in laboratory parameters</measure>
    <time_frame>up to day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in vital signs</measure>
    <time_frame>up to day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>up to 1 year</time_frame>
    <description>according to the response evaluation criteria in solid tumours (RECIST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of bivatuzumab mertansine</measure>
    <time_frame>up to day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of CD44v6 recognising IgG antibodies (anti-CD44v6-IgG)</measure>
    <time_frame>up to day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with development of human anti-human antibodies (HAHA)</measure>
    <time_frame>up to day 21</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <arm_group>
    <arm_group_label>bivatuzumab mertansine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose escalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bivatuzumab mertansine</intervention_name>
    <arm_group_label>bivatuzumab mertansine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. male and female patients aged 18 years or older

          2. patients with histologically confirmed squamous cell carcinoma of the head and neck

          3. patients with local and / or regional recurrent disease or distant metastases who are
             refractory to or not amenable to established treatments

          4. measurable tumour deposits by one or more radiological techniques (MRI, CT)

          5. life expectancy of at least 6 months

          6. Eastern Cooperative Oncology Group (ECOG) performance score ≤ 2

          7. patients must have given written informed consent (which must be consistent with
             International Conference of Harmonisation-Good Clinical Practice (ICH-GCP) and local
             legislation)

        Exclusion Criteria:

          1. hypersensitivity to humanised or murine antibodies, immunoconjugates or the excipients
             of the trial drugs

          2. known secondary malignancy requiring therapy

          3. active infectious disease

          4. brain metastases

          5. neuropathy grade 2 or above (excluding pre-existing neuropathy of cranial nerves due
             to surgery, radiotherapy or tumour growth)

          6. absolute neutrophil count less than 1,500/mm3

          7. platelet count less than 100,000/mm3

          8. bilirubin greater than 1.5 mg/dl (&gt; 26 μmol/L, système internationale (SI) unit
             equivalent)

          9. aspartate amino transferase (AST) and/or alanine amino transferase (ALT) greater than
             3 times the upper limit of normal

         10. serum creatinine greater than 1.5 mg/dl (&gt; 132 μmol/L, SI unit equivalent)

         11. concomitant non-oncological diseases which are considered relevant for the evaluation
             of the safety of the trial drug

         12. chemo- or immunotherapy within the past three weeks prior to treatment with the trial
             drug or during the trial

         13. radiotherapy to head and neck region within the past four weeks before inclusion or
             during the trial

         14. men and women who are sexually active and unwilling to use a medically acceptable
             method of contraception

         15. pregnancy or lactation

         16. treatment with other investigational drugs or participation in another clinical trial
             within the past three weeks before start of therapy or concomitantly with this trial

         17. patients unable to comply with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2014</study_first_submitted>
  <study_first_submitted_qc>September 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2014</study_first_posted>
  <last_update_submitted>September 30, 2014</last_update_submitted>
  <last_update_submitted_qc>September 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maytansine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

